Overall survival (OS) from the phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) signaling inhibitor, in AR+ advanced triple-negative...

Date 26 September 2015
Event European Cancer Congress 2015
Session Breast Cancer - Advanced Disease
Topics Breast Cancer, Metastatic
Presenter Cortés, J.